RareCyte Revenue and Competitors

Seattle, WA USA

Location

$76M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • RareCyte's estimated annual revenue is currently $13.2M per year.(i)
  • RareCyte received $30.0M in venture funding in August 2017.
  • RareCyte's estimated revenue per employee is $155,000
  • RareCyte's total funding is $76M.

Employee Data

  • RareCyte has 85 Employees.(i)
  • RareCyte grew their employee count by 2% last year.

RareCyte's People

NameTitleEmail/Phone
1
Sr. VP EngineeringReveal Email/Phone
2
VP, FinanceReveal Email/Phone
3
SVP, EngineeringReveal Email/Phone
4
VP, Biopharma Services R&DReveal Email/Phone
5
SVP Biopharma PartnershipsReveal Email/Phone
6
VP, Customer SuccessReveal Email/Phone
7
SVP, Bio R&DReveal Email/Phone
8
Head Legal CounselReveal Email/Phone
9
Chief Financial OfficerReveal Email/Phone
10
Director, Biopharma PartnershipsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$48.2M1929%N/AN/A
Add Company

What Is RareCyte?

RareCyte is a company focused on characterizing and isolating rare cells from blood. We develop innovative products for applications in life science, pathology and clinical research as well as drug development and diagnostics. Our tools and solutions help answer difficult questions related to cancer, prenatal health, and infectious disease. RareCyte's unique technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$76M

Total Funding

85

Number of Employees

$13.2M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RareCyte News

2021-09-14 - RareCyte Secures $24M Financing

RareCyte, Inc., a Seattle, WA-based Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, raised $24M in financing. Arboretum Ventures led the financing joined by other new investors F-Prime Capital, Logos Capital, and Agilent Technologie ...

2021-09-10 - Seattle startup RareCyte raises $24M to advance new high-speed cell imaging platform

Different immune cells imaged on a section of tonsil by the RareCyte Orion platform. Distinct cell types are in green, red and white, cell nuclei are in blue. (RareCyte Image) Seattle-based startup RareCyte announced $24 million in new funding on Thursday to advance its applications for the ana ...

2021-09-10 - RareCyte, Inc. announced that it has received $24.046147 million in funding from Arboretum Ventures LLC, F Prime, Inc., Agilent Technologies, Inc., HealthQuest Capital, 5AM Venture Management, LLC

On September 10, 2021, RareCyte, Inc. closed the transaction. The company has received $46,147 in its second and final tranche closing. The company raised a total of $24,046,147 in the transaction from 27 investors.

2019-09-03 - Brown University, PerkinElmer Develop Label-Free Method to ...

... and used CyteFinder and CytePicker technology from RareCyte, to which they had access through PerkinElmer, to pick individual trophoblast ...

2019-09-03 - RareCyte expands liquid biopsy offerings with the RarePlex ...

RareCyte expands liquid biopsy offerings with the RarePlex™ CTC Developer Kit for custom biomarkers, and introduces the next generation ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M8555%N/A
#2
$27.5M85-10%N/A
#3
$27.5M858%N/A
#4
$11.9M850%$26.3M
#5
$15.9M856%N/A

RareCyte Funding

DateAmountRoundLead InvestorsReference
2012-08-24$UndisclosedUndisclosedTelegraph Hill PartnersArticle
2017-08-30$30.0MUndisclosed5AM VenturesArticle